Why the study?
Do single oral doses of thioridazine or mesoridazine increase the QTc interval in healthy adults compared to placebo?
Do single oral doses of thioridazine or mesoridazine increase the QTc interval in healthy adults compared to placebo?
Both thioridazine and mesoridazine significantly prolong the QTc interval in healthy adults compared to placebo, indicating a potential risk for arrhythmias.
Thioridazine and mesoridazine prolong QTc more than placebo; confirms arrhythmogenic risk and supports restricted use with ECG monitoring.
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study. Mean maximum increases in the QTc interval following thioridazine (37.3+/-4.1 ms, P=0.023) and mesoridazine (46.6+/-7.4 ms, P=0.021) were similar and significantly greater than following placebo (12.9+/-8.1 ms). The area under the effect-time curve over 8 h following drug administration was similar between the two drugs (129.3+/-22.1 vs 148.3+/-43.0 ms h). In conclusion, thioridazine and mesoridazine are associated with similar effects on the QTc interval.
No takes yet. Share an insight, caveat, or question.
Salih et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: